Sign In
Buy AEMD
$1.36
-0.0200 (-1.45%)
At Close: Jun 23, 2026
Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 27, 2024
08:01am, Friday, 21'st Jun 2024
SAN DIEGO , June 21, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases,
What's Next in Treatments for Cancer Patients with Solid Tumors?
07:00am, Thursday, 20'th Jun 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 20, 2024) - Investorideas.com, a go-to investing platform, releases an industry snapshot looking at the future treatment of soli
Aethlon Medical Receives Ethics Committee Approval for Hemopurifier® Cancer Trial
08:01am, Tuesday, 18'th Jun 2024
Aethlon Medical Granted Full Ethics Approval From the Human Research Ethics Committee at Central Adelaide Local Health Network for a Safety, Feasibility, and Dose Finding Study of its Hemopurifier® i
The Hunt for Virus Treatments Continues Post Covid-19
08:00am, Friday, 07'th Jun 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 7, 2024) - Investorideas.com, a go-to investing platform, releases the second of a two-part series looking at news and developme
Why Is Aethlon Medical (AEMD) Stock Up 82% Today?
08:12am, Thursday, 06'th Jun 2024
Aethlon Medical (NASDAQ: AEMD ) stock is soaring higher on Thursday alongside strong pre-market trading for the medical therapeutic company's shares. Aethlon Medical is experiencing heavy trading tod
Blood Purification Medical Devices Revolutionizing the Future of Health from Cancer to COVID
09:05am, Monday, 03'rd Jun 2024
Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - June 3, 2024) - Investorideas.com, a go-to investing platform, releases the first of a two-part series looking at medical device adva
Aethlon Medical Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies
08:01am, Monday, 03'rd Jun 2024
Phase 1 Clinical Trials of the Hemopurifier® Designed to Include Patients With Solid Tumors Who Have Stable or Progressive Disease During Anti-PD-1 Monotherapy Treatment, Such as Keytruda® of Opdivo
Aethlon Medical Announces Pricing of $4.7 Million Public Offering
09:15am, Wednesday, 15'th May 2024
SAN DIEGO , May 15, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, to
Translational Study Provides Pre-Clinical Evidence to Support The Design of a Phase 1 Study of the Hemopurifier In Cancer Patients With Solid Tumors Treated With Anti-PD-1 Antibodies SAN DIEGO , May 1
Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices
08:01am, Wednesday, 21'st Feb 2024
Aethlon Medical Will Perform Pre-Clinical Studies to Explore Potential Synergies With its First-in-Class Hemopurifier® Blood Filtration System SAN DIEGO , Feb. 21, 2024 /PRNewswire/ -- Aethlon Medica
Aethlon Medical, Inc. (AEMD) Q3 2024 Earnings Call Transcript
09:17pm, Wednesday, 14'th Feb 2024
Aethlon Medical, Inc. (AEMD) Q3 2024 Earnings Call Transcript
Aethlon Medical Announces Fiscal Third Quarter Financial Results and Provides Corporate Update
04:15pm, Wednesday, 14'th Feb 2024
Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO , Feb. 14, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat c
Aethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 14, 2024
08:00am, Wednesday, 07'th Feb 2024
SAN DIEGO , Feb. 7, 2024 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, to
Aethlon Medical, Inc. (AEMD) Q2 2024 Earnings Call Transcript
10:01pm, Tuesday, 14'th Nov 2023
Aethlon Medical, Inc. (NASDAQ:AEMD ) Q2 2024 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Michael Miller - Rx Communications, IR Jim Frakes - Interim CEO and CFO Steven L
Aethlon Medical Announces Fiscal Second Quarter Financial Results and Provides Corporate Update
04:15pm, Tuesday, 14'th Nov 2023
Conference Call to be Held Today at 4:30 p.m. ET SAN DIEGO , Nov. 14, 2023 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat c
